hotspot -WSS

hotspot

author：fashion 2025-08-06 04:47:30 - browse：4

illustration of a colorful DNA strand, partly broken into pieces. -- health coverage from STAT — Adobe

BALTIMORE — An ambitious effort to cure HIV with CRISPR genome editing fell short in an early clinical trial, investigators announced Friday morning.

In the study, run by Excision BioTherapeutics, researchers tried to use the gene editing tool to address a chief reason HIV has been so hard to cure. While antiviral drugs can clear patients of replicating virus, HIV is able to worm its way into a patients’ own DNA in certain cells. If the patient ever stops taking medicines, those cells start pumping out HIV particles and the infection roars back.

Researchers hoped they could send CRISPR to those cells and, by cutting the HIV DNA lurking there at two spots, slice out the virus. In the Phase 1 trial, investigators administered the treatment to five patients. They then took three of them off conventional antiviral treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： As health system earnings go up, health insurance stocks go down

leisure time

explore

WSS

Pfizer highlights cancer drugs it thinks could reignite investor interest

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Has Bernie Sanders reached the limit of his pharma bullying effort?

Brain technologies pose threats that are all too real, experts warn

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

FogPharma raises $145 million in rare Series E round

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Duchenne breakthrough therapy leaves behind pioneering families

Primary care doctor shortage won't be solved by free med school tuition

The cancer drug shortage isn’t new — and neither are the solutions

Brain technologies pose threats that are all too real, experts warn

Peter Hotez and the public health issue of online harassment

As billionaires fund anti

Medical leaders decry Supreme Court decision on affirmative action

Chemotherapy before breast cancer surgery might fuel metastasis

Alkermes shareholders re

How to address the problem of discarded donor organs

entertainment

As health system earnings go up, health insurance stocks go down

BIO to announce reorganization, senior leaders expected to depart

Scientists unlock the key to scar

As health system earnings go up, health insurance stocks go down

Pfizer highlights cancer drugs it thinks could reignite investor interest

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

leisure time

hotspot

explore

entertainment